GHRP-2 and GHRP-6 - Growth Hormone Releasing Peptides

GHRP-2 and GHRP-6: Synthetic Growth Hormone-Releasing Peptides for Endocrine Research

1. Introduction

Growth hormone-releasing peptides (GHRPs) are a family of synthetic oligopeptides that potently stimulate the secretion of growth hormone (GH) from the anterior pituitary gland. GHRP-2 (Pralmorelin, KP-102, CAS 158861-67-7) and GHRP-6 (growth hormone-releasing hexapeptide, CAS 87616-84-0) are the most well-characterized members of this class. Both are synthetic hexapeptides that act as agonists of the ghrelin receptor (GHS-R1a), mimicking the action of the endogenous hormone ghrelin. They have been extensively studied for their potential in diagnosing and treating GH deficiency, as well as for their anabolic, lipolytic, and metabolic effects.

2. Chemical Structure and Properties

GHRP-2 and GHRP-6 are structurally distinct hexapeptides:

GHRP-2 is also known as Pralmorelin, KP-102, or GPA-748. GHRP-6 is sometimes referred to as SKF 110679.

3. Mechanism of Action

Both peptides exert their effects by binding to and activating the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor, which is expressed in the hypothalamus and pituitary gland. Activation of this receptor triggers intracellular signaling cascades that lead to the release of growth hormone from pituitary somatotrophs. GHRP-2 acts at both hypothalamic and pituitary sites to stimulate GH release. GHRP-6 activates the inositol trisphosphate/diacylglycerol pathway in anterior pituitary cells.

The GH-releasing effect of GHRP-2 is synergistic with GHRH (growth hormone-releasing hormone). GHRP-6 stimulates GH secretion both by acting directly on the pituitary gland and indirectly via hypothalamic GRF.

4. Pharmacokinetics

Both peptides have short half-lives due to rapid degradation in vivo:

• GHRP-2: Biological half-life is approximately 30 minutes, with peak GH concentration reached about 15 minutes after administration.

• GHRP-6: Orally active in humans, with GH-releasing activity demonstrated after oral administration.

5. Research Applications and Effects

Growth Hormone Stimulation: Both peptides are potent GH secretagogues. GHRP-2 has been studied as a diagnostic agent for GH deficiency and has been shown to stimulate GH secretion in GH-deficient patients with mutated GHRH receptors.

Metabolic Effects: Both peptides increase food intake in humans by mimicking ghrelin's orexigenic action. GHRP-6 produces the most intense appetite stimulation among all GHRPs. GHRP-2 produces moderate appetite stimulation, less than GHRP-6.

Anabolic and Lipolytic Effects: Both peptides have been studied for their potential to promote muscle growth, reduce fat mass, and improve metabolic function.

6. Safety and Adverse Effects

The safety profile differs between the two peptides:

GHRP-6: Clinical trials have reported adverse events including sweating (50%), bradycardia (44.4%), and sleepiness (16.7%). In animal studies at high doses (1000–2000 μg/kg/day), hypersalivation, hypoactivity, reduced heart rate, and changes in respiration were observed. Both peptides may elevate prolactin and cortisol levels, with GHRP-2 showing a more pronounced effect on cortisol. GHRP-6 has also been associated with dysglycemia, fluid retention, myalgia, and arthralgia.

GHRP-2: May increase prolactin and cortisol more significantly than GHRP-6. As a GH secretagogue, it is listed as a prohibited substance by the World Anti-Doping Agency (WADA).

7. Research and Development Prospects

GHRP-2 (Pralmorelin) has been investigated as a diagnostic agent for GH deficiency and for the treatment of pituitary disorders. Both peptides continue to be studied for their potential in treating muscle wasting, metabolic disorders, and age-related conditions.

8. Conclusion

GHRP-2 (Pralmorelin, CAS 158861-67-7) and GHRP-6 (CAS 87616-84-0) are potent synthetic hexapeptide ghrelin receptor agonists that stimulate growth hormone release through activation of GHS-R1a. While they share a common mechanism of action, they differ in their chemical structures, pharmacokinetic profiles, and side effect spectra. GHRP-2 is characterized by a shorter half-life (approximately 30 minutes) and a greater effect on cortisol and prolactin, while GHRP-6 produces more intense appetite stimulation and has a distinct safety profile. Both peptides are valuable research tools for studying GH regulation, metabolism, and potential therapeutic applications in GH deficiency and related disorders. Their use in humans is regulated, and they are prohibited in competitive sports by WADA.